ATE277933T1 - Thiophenverbindungen zur verwendung als antikrebsmittel - Google Patents

Thiophenverbindungen zur verwendung als antikrebsmittel

Info

Publication number
ATE277933T1
ATE277933T1 AT01925786T AT01925786T ATE277933T1 AT E277933 T1 ATE277933 T1 AT E277933T1 AT 01925786 T AT01925786 T AT 01925786T AT 01925786 T AT01925786 T AT 01925786T AT E277933 T1 ATE277933 T1 AT E277933T1
Authority
AT
Austria
Prior art keywords
anticancer agents
thiophene compounds
thiophene
compounds
anticancer
Prior art date
Application number
AT01925786T
Other languages
English (en)
Inventor
Michael Joseph Luzzio
Matthew Arnold Marx
Bingwei Vera Yang
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Application granted granted Critical
Publication of ATE277933T1 publication Critical patent/ATE277933T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
AT01925786T 2000-06-06 2001-05-02 Thiophenverbindungen zur verwendung als antikrebsmittel ATE277933T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US20968600P 2000-06-06 2000-06-06
PCT/IB2001/000766 WO2001094353A1 (en) 2000-06-06 2001-05-02 Thiophene derivatives useful as anticancer agents

Publications (1)

Publication Number Publication Date
ATE277933T1 true ATE277933T1 (de) 2004-10-15

Family

ID=22779830

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01925786T ATE277933T1 (de) 2000-06-06 2001-05-02 Thiophenverbindungen zur verwendung als antikrebsmittel

Country Status (23)

Country Link
US (1) US6964961B2 (de)
EP (1) EP1287001B1 (de)
JP (1) JP2003535867A (de)
AR (1) AR032621A1 (de)
AT (1) ATE277933T1 (de)
AU (1) AU2001252463A1 (de)
BR (1) BR0111377A (de)
CA (1) CA2411084A1 (de)
DE (1) DE60106022T2 (de)
DO (1) DOP2001000170A (de)
EC (1) ECSP014097A (de)
ES (1) ES2223827T3 (de)
GT (1) GT200100104A (de)
MX (1) MXPA02012034A (de)
PA (1) PA8518701A1 (de)
PE (1) PE20011373A1 (de)
PT (1) PT1287001E (de)
PY (1) PY0111330A (de)
SV (1) SV2002000478A (de)
TN (1) TNSN01082A1 (de)
TR (1) TR200402656T4 (de)
UY (1) UY26750A1 (de)
WO (1) WO2001094353A1 (de)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1193255A4 (de) * 1999-07-01 2002-08-07 Ajinomoto Kk Heterozyklische verbindungen und ihre medizinische anwendung
US20030207878A1 (en) * 2000-08-09 2003-11-06 Hennequin Lawrent Francois Andre Chemical compounds
DE10164139A1 (de) 2001-12-27 2003-07-10 Bayer Ag 2-Heteroarylcarbonsäureamide
WO2003064411A1 (en) * 2002-02-01 2003-08-07 Novo Nordisk A/S Amides of aminoalkyl-substituted azetidines, pyrrolidines, piperidines and azepanes
US7101898B2 (en) 2002-02-01 2006-09-05 Novo Nordisk A/S Amides of aminoalkyl-substituted azetidines, pyrrolidines, piperidines and azepanes
MXPA04008403A (es) * 2002-03-01 2004-11-26 Pfizer Indolil-urea derivados de tienopiridinas utiles como agentes antiangiogenicos, y procedimientos para su uso.
BR0311605A (pt) * 2002-06-06 2005-02-22 Boehringer Ingelheim Pharma Compostos de amida de ácido 3-aminotieno[2,3-b]piridina-2-carboxìlico substituìdo e processos para preparação e seus usos
UA77303C2 (en) 2002-06-14 2006-11-15 Pfizer Derivatives of thienopyridines substituted by benzocondensed heteroarylamide useful as therapeutic agents, pharmaceutical compositions and methods for their use
US7488823B2 (en) * 2003-11-10 2009-02-10 Array Biopharma, Inc. Cyanoguanidines and cyanoamidines as ErbB2 and EGFR inhibitors
US7276519B2 (en) * 2002-11-25 2007-10-02 Wyeth Thieno[3,2-b]pyridine-6-carbonitriles and thieno[2,3-b]pyridine-5-carbonitriles as protein kinase inhibitors
CL2003002287A1 (es) 2002-11-25 2005-01-14 Wyeth Corp COMPUESTOS DERIVADOS DE TIENO[3,2-b]-PIRIDINA-6-CARBONITRILOS Y TIENEO[2,3-b]-PIRIDINA-5-CARBONITRILOS, COMPOSICION FARMACEUTICA, PROCEDIMIENTO DE PREPARACION Y COMPUESTOS INTERMEDIARIOS, Y SU USO EN EL TRATAMIENTO DEL CANCER, APOPLEJIA, OSTEOPOROSIS
UA81453C2 (en) 2003-02-27 2008-01-10 Pyrazolopyridine derivates
US7592352B2 (en) * 2003-05-06 2009-09-22 Smithkline Beecham Corporation Substituted thieno and furo-pyridines
US7501427B2 (en) 2003-08-14 2009-03-10 Array Biopharma, Inc. Quinazoline analogs as receptor tyrosine kinase inhibitors
JP4828421B2 (ja) 2003-08-14 2011-11-30 アレイ バイオファーマ、インコーポレイテッド 受容体チロシンキナーゼ阻害剤としてのキナゾリン誘導体
US7459562B2 (en) 2004-04-23 2008-12-02 Bristol-Myers Squibb Company Monocyclic heterocycles as kinase inhibitors
TW200538453A (en) 2004-04-26 2005-12-01 Bristol Myers Squibb Co Bicyclic heterocycles as kinase inhibitors
US7432373B2 (en) 2004-06-28 2008-10-07 Bristol-Meyers Squibb Company Processes and intermediates useful for preparing fused heterocyclic kinase inhibitors
US7439246B2 (en) 2004-06-28 2008-10-21 Bristol-Myers Squibb Company Fused heterocyclic kinase inhibitors
US20050288290A1 (en) 2004-06-28 2005-12-29 Borzilleri Robert M Fused heterocyclic kinase inhibitors
EP1781664B1 (de) 2004-07-30 2013-09-04 MethylGene Inc. Inhibitoren von vegf-rezeptor- und hgf-rezeptor-signalvermittlung
MX2007014617A (es) 2005-05-20 2008-02-11 Methylgene Inc Inhibidores de senalizacion de receptor de factor de crecimiento endotelial bascular y receptor de factor de crecimiento de hepatocitos.
WO2008041053A2 (en) 2005-05-20 2008-04-10 Methylgene, Inc. Inhibitors of vegf receptor and hgf receptor signaling
WO2007035428A1 (en) 2005-09-15 2007-03-29 Bristol-Myers Squibb Company Met kinase inhibitors
AR056200A1 (es) * 2005-09-27 2007-09-26 Wyeth Corp Tieno [2,3-b]piridin-5-carbonitrilos como inhibidores de proteina quinasa
US7547782B2 (en) 2005-09-30 2009-06-16 Bristol-Myers Squibb Company Met kinase inhibitors
DE602006021645D1 (de) 2005-11-15 2011-06-09 Array Biopharma Inc Verfahren und Zwischenverbindungen zur Herstellung von N4-Phenyl-Quinazolin-4-Amin Derivaten
US8003662B2 (en) * 2006-01-30 2011-08-23 Array Biopharma, Inc. Heterobicyclic thiophene compounds and methods of use
ES2470341T3 (es) 2007-04-05 2014-06-23 Amgen, Inc Moduladores de la aurora cinasa y método de uso
MX2010009729A (es) 2008-03-05 2010-12-21 Methylgene Inc Inhibidores de actividad de proteina tirosina quinasa.
AU2009226024B2 (en) 2008-03-20 2012-07-12 Amgen Inc. Aurora kinase modulators and method of use
WO2010019473A1 (en) 2008-08-14 2010-02-18 Amgen Inc. Aurora kinase modulators and methods of use
HUE026815T2 (en) 2008-11-19 2016-07-28 Forum Pharmaceuticals Inc Treatment of Cognitive Disorders with (R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide and pharmaceutically acceptable salts thereof
AU2010247835A1 (en) * 2009-05-11 2011-12-08 Envivo Pharmaceuticals, Inc. Treatment of cognitive disorders with certain alpha-7 nicotinic acid receptors in combination with acetylcholinesterase inhibitors
TWI519532B (zh) 2010-05-17 2016-02-01 艾維沃製藥公司 （Ｒ）－７－氯－Ｎ－（啶－３－基）苯並［b］噻吩－２－羧醯胺鹽酸鹽單水合物之結晶形體
RU2017136693A (ru) 2012-05-08 2019-02-08 Форум Фармасьютикалз, Инк. Способы поддержания, лечения или улучшения когнитивной функции
FR3080620B1 (fr) * 2018-04-27 2021-11-12 Univ Paris Sud Composes a activite inhibitrice de la polymerisation de la tubuline et aux proprietes immunomodulatrices
CN113648307B (zh) * 2021-09-23 2022-09-30 河南大学 MII-tt-DTT及其在制备抗结直肠癌药物中的应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0071227B1 (de) 1981-07-31 1987-11-11 Sloan-Kettering Institute For Cancer Research Beta-Glycosyl C-Nucleoside mit anti-leukemischer Wirkung
EP0364598A4 (en) 1988-03-02 1992-01-15 Yoshitomi Pharmaceutical Industries, Ltd. 3,4-dihydrothieno 2,3-d¨pyrimidine compounds and pharmaceutical application thereof
JPH02256667A (ja) * 1988-12-27 1990-10-17 Masatoshi Yamato 縮合キノリン系化合物およびその製造方法
AU651337B2 (en) 1990-03-30 1994-07-21 Dowelanco Thienopyrimidine derivatives
US5187168A (en) * 1991-10-24 1993-02-16 American Home Products Corporation Substituted quinazolines as angiotensin II antagonists
FI943798A7 (fi) 1992-02-19 1994-08-18 Pfizer Kasvaimenvastaisen vaikutuksen lisäämiseen tarkoitettuja heterosyklisi ä yhdisteitä
IL112249A (en) 1994-01-25 2001-11-25 Warner Lambert Co Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds
US5654307A (en) * 1994-01-25 1997-08-05 Warner-Lambert Company Bicyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family
CA2223081C (en) 1995-06-07 2001-03-06 Pfizer Inc. Heterocyclic ring-fused pyrimidine derivatives
AR004010A1 (es) 1995-10-11 1998-09-30 Glaxo Group Ltd Compuestos heterociclicos
DK0778277T3 (da) 1995-12-08 2003-10-27 Pfizer Substituerede heterocycliske derivater som CRF antagonister
JP2000504678A (ja) 1996-02-07 2000-04-18 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ チオフェノピリミジン類
IL129825A0 (en) 1996-11-27 2000-02-29 Pfizer Fused bicyclic pyrimidine derivatives
ZA986729B (en) * 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitors of tyrosine kinases
SK6652000A3 (en) * 1997-11-11 2002-05-09 Pfizer Prod Inc Thienopyrimidine and thienopyridine derivatives useful as anticancer agents

Also Published As

Publication number Publication date
SV2002000478A (es) 2002-07-03
PA8518701A1 (es) 2002-09-17
GT200100104A (es) 2002-01-31
EP1287001B1 (de) 2004-09-29
UY26750A1 (es) 2002-01-31
PY0111330A (es) 2003-11-03
DOP2001000170A (es) 2002-05-15
JP2003535867A (ja) 2003-12-02
DE60106022T2 (de) 2006-03-09
WO2001094353A1 (en) 2001-12-13
US6964961B2 (en) 2005-11-15
TNSN01082A1 (fr) 2005-11-10
BR0111377A (pt) 2003-06-03
ECSP014097A (es) 2003-02-06
AR032621A1 (es) 2003-11-19
ES2223827T3 (es) 2005-03-01
MXPA02012034A (es) 2003-04-25
CA2411084A1 (en) 2001-12-13
EP1287001A1 (de) 2003-03-05
TR200402656T4 (tr) 2004-11-22
US20020042409A1 (en) 2002-04-11
AU2001252463A1 (en) 2001-12-17
PE20011373A1 (es) 2002-01-18
PT1287001E (pt) 2004-12-31
DE60106022D1 (de) 2004-11-04

Similar Documents

Publication Publication Date Title
DE60106022D1 (de) Thiophenverbindungen zur verwendung als antikrebsmittel
DE60115937D1 (de) Piperidinverbindungen zur verwendung als antiallergika
ATE485272T1 (de) Polyarylcarboxamide zur verwendung als lipidsenker
NO20032585L (no) ABCA-1 forhoyende forbindelser
NO20026196L (no) Kinazolinditosylatsalt-forbindelser
DK1619192T3 (da) Arylkondeserede azapolycykliske forbindelser
EE200200082A (et) Uued spiroühendid
IS6024A (is) Ný efnasambönd
IS6239A (is) Ný efnasambönd
AR027983A1 (es) Novedosos compuestos
IS6139A (is) Ný efnasambönd
ATE428420T1 (de) Substituierte 8-arylchinoline als phosphodiesterase-4-hemmer
DE50011908D1 (de) 16-hydroxyestratriene als selektiv wirksame estrogene
DE50107230D1 (de) Sulfamidothienopyrimidine zur verwendung als phosphodiesterase v-hemmer
NO20025659L (no) Heterocykliske forbindelser
IS6657A (is) Ný efnasambönd
AR028220A1 (es) Novedosos compuestos
ATE372338T1 (de) Deshalogenverbindungen
NO20023508L (no) Kalsilyttiske forbindelser
NO20031837L (no) Kalsilytiske forbindelser
ATE280161T1 (de) Imidazolverbindungen als alpha2-adrenorezeptoren antagonisten
SE0004611D0 (sv) Novel Compounds
SE0003436D0 (sv) Novel compounds
SE0003437D0 (sv) Novel compounds
SE0002234D0 (sv) Novel compounds

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1287001

Country of ref document: EP

REN Ceased due to non-payment of the annual fee